Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

A reduction in BCR-ABL1/ABL1(IS) transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple BCR-ABL1 th...

Descripción completa

Detalles Bibliográficos
Autores principales: Stella, Stefania, Zammit, Valentina, Vitale, Silvia Rita, Pennisi, Maria Stella, Massimino, Michele, Tirrò, Elena, Forte, Stefano, Spitaleri, Antonio, Antolino, Agostino, Siragusa, Sergio, Accurso, Vincenzo, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Russo, Sabina, Malato, Alessandra, Mineo, Giuseppe, Musso, Maurizio, Porretto, Ferdinando, Martino, Bruno, Di Raimondo, Francesco, Manzella, Livia, Vigneri, Paolo, Stagno, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539817/
https://www.ncbi.nlm.nih.gov/pubmed/31064152
http://dx.doi.org/10.3390/ijms20092226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539817/
https://www.ncbi.nlm.nih.gov/pubmed/31064152
http://dx.doi.org/10.3390/ijms20092226

Ejemplares similares